If you run an aesthetic clinic in the UK, you already know the headline: you're not allowed to advertise Botox.
What you might not know is exactly where the lines are — and how much room there actually is on the legal side of those lines, if you understand the system properly.
Here's the working version, in plain language, with a focus on what you can do rather than just what you can't.
Disclaimer: This is a practical overview, not legal advice. Always check current ASA, MHRA, and JCCP guidance — and where in doubt, run materials past a regulated marketing lawyer or the ASA Copy Advice service.
What's actually prohibited
The UK rule, simplified: you cannot advertise prescription-only medicines (POMs) to the public. Botulinum toxin (Botox, Bocouture, Azzalure, Letybo, etc.) is a POM. Therefore you cannot advertise it by name.
That includes:
- The product name in any marketing copy seen by the public
- Images that obviously depict the product or its administration
- Discounts, "deals" or "offers" tied to the product
- Suggesting the public should ask for or receive the product
The MHRA enforces the underlying medicines law. The ASA enforces the advertising code that mirrors it. Both have been more active in this space recently — and the ASA has been notably aggressive about social media, including influencer posts.
Dermal fillers in the UK are not currently classified as POMs (this differs from the US), so the strict POM advertising ban doesn't apply. But the ASA still requires that filler advertising be responsible, evidenced, and not misleading — and the regulatory direction of travel is clearly towards more restriction, not less.
What you absolutely can do
This is where most clinics under-use the available space.
Talk about treatments at the category level. You can advertise "wrinkle reduction consultations," "anti-ageing treatments," or "prescription injectable consultations." You can describe what these treatments achieve, who they're for, and what to expect — as long as you don't name the prescription product.
Promote consultations. A consultation isn't a prescription medicine. You can market the consultation itself extensively — what's covered, who conducts it, what makes it different.
Educate. Educational content about ageing, skin, the science behind treatments, and how to choose a practitioner is not advertising. It's editorial. It's also exactly the content AI engines reward.
Showcase your practitioners. A named, credentialed clinical lead with a real story isn't advertising a medicine — it's advertising expertise. This is one of the highest-conversion things you can put on a website, and it's almost entirely unrestricted.
Tell patient stories. With proper consent, you can share patient experiences in your own marketing. The line is fuzzy — you can't make medical claims, you can't reference the prescription product by name, and you should be careful with before-and-afters of POM treatments — but there's real space to operate here.
Build third-party authority. You can be quoted in press. You can appear on podcasts. You can write expert pieces for industry publications. None of that is regulated as direct-to-public advertising in the way social media or your own site is.
Where AI visibility quietly helps
Here's the part most clinics miss.
Almost all the regulatory restrictions apply to advertising — paid promotion of named prescription products to the public. They don't apply to:
- A patient asking ChatGPT a question and getting a recommendation
- An AI summarising your clinic's expertise based on your existing legal content
- A model citing third-party press coverage about your clinical lead
This means AI visibility is a channel that operates almost entirely outside the most restrictive advertising rules. You're not buying placement. You're not running ads. The model is responding to organic signals — your content, your press, your association directory entries, your patient reviews.
For a clinic that's spent the last five years watching paid channels close one by one, this is genuinely good news.
What about Ireland?
Ireland's regulatory landscape is broadly similar but stricter in some areas. The HPRA (Health Products Regulatory Authority) enforces medicines law and tends to take a conservative line on cosmetic injectable advertising. The Advertising Standards Authority for Ireland (ASAI) has its own code, which closely mirrors the UK's.
In practice, if your marketing complies with UK rules, it's likely to comply with Irish rules — but the inverse isn't always true. If you're operating in both markets, build to the stricter standard.
A practical framework
When evaluating any new piece of marketing, three questions:
- Does it name a prescription product? If yes, it's almost certainly not allowed in public-facing material.
- Does it make a medical claim? If yes, you need evidence and you need to be careful about how it's framed.
- Is it consultation-led, expertise-led, or education-led? If yes, you almost certainly have room to operate.
Most clinics reflexively under-market because they assume the rules are stricter than they are. The safer reflex is to invest more aggressively in the channels and content that are permitted — and let the channels that aren't go quiet.
AI visibility happens to be the highest-leverage of those permitted channels. Not because of a clever loophole, but because the entire mechanism — patients asking questions, models drawing on organic signals — sits naturally outside the advertising regime.
Where to start
If you'd like to see how AI is currently representing your clinic — entirely within the existing regulatory framework — we'll run a free audit and walk you through what we find.